Critical Endpoints in Bipolar Disorder Research:
Challenges and Innovations

INGENŪ CRO

Introduction

Throughout the 20th century, research into bipolar disorder expanded, leading to a greater understanding of its biological underpinnings and treatment options.

The understanding of bipolar disorder has evolved significantly over the centuries. Ancient Greek and Roman physicians, such as Hippocrates, documented mood disorders that resembled bipolar disorder, describing them as "melancholia" and "mania." However, it was not until the 19th century that bipolar disorder began to be understood as a distinct mental health condition.

The modern conceptualization of bipolar disorder began with the work of German psychiatrist Emil Kraepelin in the late 1800s. Kraepelin differentiated bipolar disorder from other types of mood disorders by observing the cyclical nature of mood episodes. He coined the term "manic-depressive illness" to describe the condition, emphasizing its episodic course.

The advent of psychopharmacology in the mid-20th century, particularly the discovery of lithium as an effective mood stabilizer, revolutionized the treatment of bipolar disorder.

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Key Characteristics and Contributing Factors

Key Characteristics

Bipolar disorder, also referred to as manic-depressive illness, is a chronic mental health condition marked by significant mood swings, including episodes of mania or hypomania and episodes of depression. These mood swings can range from extreme highs, characterized by heightened energy, euphoria, or irritability, to severe lows, characterized by sadness, hopelessness, or low energy.

Mania is typically characterized by a period of abnormally elevated mood and increased activity or energy, lasting at least one week. Hypomania is a milder form of mania that lasts at least four days and is not severe enough to cause significant impairment in social or occupational functioning.

Types of Bipolar Disorder

1. **Bipolar I Disorder:** Characterized by manic episodes lasting at least 7 days or severe manic symptoms requiring immediate care.
2. **Bipolar II Disorder:** Defined by a pattern of depressive episodes and hypomanic episodes, which are less severe than full manic episodes.
3. **Cyclothymic Disorder (Cyclothymia):** Periods of hypomanic symptoms and periods of depressive symptoms lasting for at least 2 years (1 year in children and adolescents) without meeting the diagnostic criteria for a hypomanic episode or depressive episode.
4. **Other Types:** BPD related to substance use or medical conditions.

Contributing Factors

Biological Factors:

- Genetics play a significant role in the development of bipolar disorder. Studies have shown that the condition tends to run in families, indicating a strong hereditary component. Researchers have identified several genetic markers that are associated with an increased risk of developing bipolar disorder, though the exact genetic mechanisms remain complex and not fully understood.

Psychological Factors:

- Psychological factors, such as stress and cognitive patterns, can influence the course of bipolar disorder. High-stress situations, such as significant life changes or traumatic events, can trigger mood episodes in individuals predisposed to the condition. Additionally, negative thinking patterns and poor coping strategies can exacerbate depressive episodes and hinder recovery.

Environmental Factors:

- Environmental factors, including life events and lifestyle choices, also play a role in the onset and progression of bipolar disorder. Traumatic events, such as the loss of a loved one or exposure to violence, can act as triggers for mood episodes. Substance abuse, including alcohol and drug use, is common among individuals with bipolar disorder and can worsen symptoms and complicate treatment.

Diagnostic Criteria

ICD-11 Codes

ICD 11 Code 6A60: Bipolar Type I Disorder

- Characterized by at least one manic or mixed episodes, which may be preceded or followed by hypomanic or major depressive episodes. Manic episodes are typically severe and can lead to significant impairment in social and occupational functioning.

ICD 11 Code 6A61: Bipolar Type II Disorder

- Bipolar II Disorder involves a pattern of depressive episodes and hypomanic episodes, but not the full-blown manic episodes seen in Bipolar I Disorder. Hypomanic episodes are less severe and do not cause significant impairment in daily functioning.

ICD 11 Code 6A62: Cyclothymic Disorder

- Characterized by chronic, fluctuating mood disturbances involving numerous periods of hypomanic symptoms and periods of depressive symptoms that do not meet the criteria for a major depressive episode. The hypomanic symptomatology may or may not be sufficiently severe or prolonged to meet the full definitional requirements of a hypomanic episode but there is no history of manic or mixed episodes. These symptoms persist for at least two years (one year in children and adolescents). The symptoms result in significant distress or significant impairment in personal, family, social, educational, and occupational areas of functioning.

DSM-5 Codes

DSM-5 Code 296.41-296.45: Bipolar 1 Disorder

- 296.41: Bipolar I Disorder, Most Recent Episode Manic, Mild
- 296.42: Bipolar I Disorder, Most Recent Episode Manic, Moderate
- 296.43: Bipolar I Disorder, Most Recent Episode Manic, Severe Without Psychotic Features
- 296.44: Bipolar I Disorder, Most Recent Episode Manic, Severe With Psychotic Features
- 296.45: Bipolar I Disorder, Most Recent Episode Manic, In Partial Remission or Full Remission

DSM-5 Code 296.89: Bipolar II Disorder

- Bipolar II Disorder is characterized by at least one hypomanic episode and one major depressive episode, without ever having a full manic episode.

DSM-5 Code 301.13: Cyclothymic Disorder

- Cyclothymic Disorder involves chronic, fluctuating mood disturbances with numerous periods of hypomanic symptoms and periods of depressive symptoms that do not meet the criteria for a major depressive episode or a hypomanic episode.

Epidemiological Landscape of Bipolar Disorder

Age

- Bipolar disorder typically emerges in late adolescence or early adulthood, with the average age of onset being around 25 years. However, it can occur at any age, including childhood and late adulthood. Early onset of bipolar disorder is associated with a more severe course of the illness, including more frequent mood episodes, higher rates of comorbid psychiatric disorders, and greater functional impairment.

Racial Groups

- Bipolar disorder affects individuals of all racial and ethnic backgrounds, with prevalence rates being relatively consistent across different groups. However, cultural factors can influence the diagnosis and treatment of bipolar disorder. In some cultures, mental health conditions, may be stigmatized, leading to delays in seeking treatment and underdiagnosis.

Gender Differences

- While the overall prevalence of bipolar disorder is similar between men and women, there are notable gender differences in the presentation and course of the illness. Women are more likely to experience rapid cycling, defined as having four or more mood episodes in a year, and mixed episodes, which involve simultaneous symptoms of mania and depression. Women with bipolar disorder are also more prone to experiencing depressive episodes, whereas men are more likely to experience manic episodes.

Location

- The prevalence of bipolar disorder is relatively consistent worldwide, but there are variations due to differences in healthcare access, cultural attitudes towards mental health, and diagnostic practices. In high-income countries with advanced healthcare systems, the diagnosis of bipolar disorder is more likely to be made, and treatment options are more readily available. In contrast, in low- and middle-income countries, limited access to mental health services and the stigma associated with mental illness can result in lower reported prevalence rates and inadequate treatment.

Genetic Predisposition

- Genetics play a significant role in the development of bipolar disorder. Family studies have shown that individuals with a first-degree relative (such as a parent or sibling) with bipolar disorder are at a significantly higher risk of developing the condition themselves. Twin studies further support the genetic basis of bipolar disorder, with concordance rates for bipolar disorder being much higher in identical twins compared to fraternal twins. Although no single gene has been identified as the cause of bipolar disorder, multiple genes are believed to contribute to its development. These genes are thought to influence the regulation of neurotransmitters and the functioning of brain circuits involved in mood regulation.

INGENŪ CRO

Challenges in Determining Endpoints in Bipolar Disorder Clinical Trials

1. Mood Stabilization:

Mood stabilization is a primary goal in treating bipolar disorder, but it is challenging to measure due to the subjective nature of mood reports and the episodic course of the disorder. Patients experience fluctuations between manic, hypomanic, and depressive states, making it difficult to assess consistent mood stabilization.

2. Quality of Life (QoL):

Quality of life is a multifaceted endpoint that includes physical, psychological, and social well-being. Measuring QoL in bipolar disorder is challenging because it is influenced by various factors, including the severity and frequency of mood episodes, comorbid conditions, and social support.

3. Functional Outcomes:

Functional outcomes, including cognitive function, social interaction, and occupational performance, are critical in evaluating treatment efficacy. However, these outcomes are influenced by multiple factors and can be challenging to quantify objectively.

4. Time to Recurrence and Relapse Prevention:

Bipolar disorder is characterized by a high risk of relapse, with many patients experiencing recurrent mood episodes despite treatment. Long follow-up periods are required to accurately measure relapse rates, and patient adherence to treatment can be variable. Likewise, a key endpoint for measuring the efficacy of medication is "Time to Relapse". Time to relapse is a critical endpoint in clinical trials for bipolar disorder, particularly in studies evaluating maintenance treatments. This endpoint measures the duration from the point of achieving clinical stability to the occurrence of a new mood episode, whether manic, hypomanic, or depressive. It provides important insights into the long-term efficacy of treatments in preventing recurrences and maintaining mood stability.

5. Adverse Effects and Tolerability:

Monitoring adverse effects and tolerability is essential for assessing the safety of treatments. Patients with bipolar disorder often require long-term medication, which can lead to cumulative side effects that impact adherence and overall health.

Pivotal Endpoints for Bipolar Disorder Clinical Trials: Effective Solutions

1. Mood Stabilization:

Standardized mood rating scales – the Young Mania Rating Scale (YMRS) for mania and the Hamilton Depression Rating Scale (HDRS) for depression – can provide objective measures of mood changes. The Montgomery-Åsberg Depression Rating Scale (MADRS) is a scale designed to measure the severity of depressive episodes in patients with mood disorders.

2. Quality of Life (QoL):

Implementing validated QoL assessment tools, such as the WHO Quality of Life (WHOQOL) questionnaire or the Short Form Health Survey (SF-36), can provide a comprehensive evaluation of a patient's quality of life. Incorporating patient-reported outcomes (PROs) in clinical trials ensures that subjective experiences and personal perspectives are considered.

3. Time to Recurrence and Relapse Prevention:

Longitudinal study designs with regular follow-up assessments are essential to monitor relapse rates. Using adherence-promoting strategies, such as mobile health interventions (e.g., apps for medication reminders and mood tracking), can help ensure consistent data collection and patient compliance.

4. Functional Outcomes:

Employing neuropsychological assessments and functional capacity measures can provide objective data on cognitive and functional abilities. Tools such as the Global Assessment of Functioning (GAF) scale or the Sheehan Disability Scale (SDS) can help quantify the impact of bipolar disorder on daily functioning.

5. Adverse Effects and Tolerability:

Regularly monitoring and documenting adverse effects through standardized scales, such as the UKU Side Effect Rating Scale or the Systematic Assessment for Treatment Emergent Events (SAFTEE), can help manage and mitigate side effects. Patient education on potential side effects and their management is crucial for promoting adherence.

Five FDA-Approved Treatments for Bipolar Disorder

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Lithium	1970	*Multiple*	• Mood stabilizer that helps to regulate mood swings • Affects the flow of sodium through nerve and muscle cells in the body, influencing the balance of neurotransmitters in the brain	• Reduces severity and frequency of mood episodes
Valproate	1996	AbbVie	• Anticonvulsant • Increases the levels of gamma-aminobutyric acid (GABA) in the brain	• Controls manic episodes • Reduces excessive neuronal firing(management of acute mania)
Olanzapine	1996	Eli Lilly	• Atypical antipsychotic • Antagonize dopamine and serotonin receptors in the brain	• Treats manic or mixed episodes • Stabilize mood and reduce psychotic symptoms
Quetiapine	1997	AstraZeneca	• Atypical antipsychotic • Serotonin and dopamine antagonist	• Effective for depressive and manic episodes • Helps prevent the recurrence of mood episodes
Lamotrigine	1994	GlaxoSmithKline	• Anticonvulsant • Inhibits glutamate release	• Prevents depressive episodes • Used as maintenance therapy to prevent relapse

Approved Product Analysis: Lithium

Adult and Pediatric Clinical Study

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Pediatric patients (ages 7 to ≤18 years) with bipolar I disorder	Acute Efficacy	YMRS	8 weeks	N=81 (53 lithium, 28 placebo)	Lithium: -12.9 (3.1), Placebo: -7.3 (3.1), Difference: -5.5 (-10.5, -0.5)
Pediatric patients (ages 7 to ≤18 years) with bipolar I disorder	All-cause Discontinuation	Discontinuation	28 weeks	N=31 (17 lithium, 14 placebo)	Hazard Ratio: 0.28 (0.10, 0.78)

Approved Product Analysis: Valproate

Epilepsy – Study 1

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with complex partial seizures (CPS)	Median Incidence of CPS	Seizure incidence rate	8 weeks	N=144 (75 Depakote, 69 placebo)	Depakote: 16.0 to 8.9, Placebo: 14.5 to 11.5, Reduction greater for Depakote ($p \leq 0.05$)

Epilepsy – Study 2

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with complex partial seizures (CPS)	Median Incidence of CPS	Seizure incidence rate	8 weeks	N=265 (131 high dose, 134 low dose)	High dose: 13.2 to 10.7, Low dose: 14.2 to 13.8, Reduction greater for high dose ($p \leq 0.05$)

Approved Product Analysis: Olanzapine

Schizophrenia – Adults

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adult inpatients with schizophrenia	6-week, placebo-controlled trial (1 mg/day and 10 mg/day olanzapine)	Treatment response	PANSS total, BPRS total, BPRS psychosis cluster, PANSS Negative subscale, CGI Severity	6 weeks	N=149	• **PANSS Total Score:** 10 mg/day superior to placebo • **BPRS Total Score:** 10 mg/day superior to placebo • **BPRS Psychosis Cluster:** 10 mg/day superior to placebo • **PANSS Negative Subscale:** 10 mg/day superior to placebo • **CGI Severity:** 10 mg/day superior to placebo
Adult inpatients with schizophrenia	6-week, placebo-controlled trial (5 ± 2.5 mg/day, 10 ± 2.5 mg/day, 15 ± 2.5 mg/day olanzapine)	Treatment response	BPRS total, BPRS psychosis cluster, CGI Severity, SANS	6 weeks	N=253	• **BPRS Total Score:** 12 mg/day and 16 mg/day superior to placebo • **BPRS Psychosis Cluster:** 12 mg/day and 16 mg/day superior to placebo • **CGI Severity:** 12 mg/day and 16 mg/day superior to placebo • **SANS:** 16 mg/day superior to placebo; no clear advantage for 16 mg/day over 12 mg/day
Adult outpatients with schizophrenia	Longer-term trial (continuation on olanzapine vs. placebo)	Time to relapse	BPRS positive symptoms, hospitalization	Up to 12 months (stopped early at 8 months)	N=326	• **Time to Relapse:** Olanzapine superior to placebo in preventing relapse • **Relapse Definition:** Increase in BPRS positive symptoms or hospitalization; trial stopped early due to excess placebo relapses

Schizophrenia – Adolescents

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adolescents (13-17 years) with schizophrenia	6-week, double-blind, placebo-controlled, randomized trial	Treatment response	BPRS-C total score	6 weeks	N=107	• **BPRS-C Total Score:** Statistically significantly greater mean reduction for olanzapine (mean modal dose 12.5 mg/day, mean dose 11.1 mg/day) compared to placebo

Approved Product Analysis: Olanzapine (cont.)

Bipolar I Disorder (Manic or Mixed Episodes) – Adults

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with bipolar I disorder (manic or mixed episodes)	3-week, placebo-controlled trial (5-20 mg/day, starting at 10 mg/day)	Treatment response	Y-MRS	3 weeks	N=67	• **Y-MRS Total Score:** Olanzapine superior to placebo in reduction of Y-MRS total score
Adults with bipolar I disorder (manic or mixed episodes)	3-week, placebo-controlled trial (identical design to first trial)	Treatment response	Y-MRS	3 weeks	N=67	• **Y-MRS Total Score:** Similar treatment difference to first trial, not superior to placebo possibly due to sample size and site variability
Adults with bipolar I disorder (manic or mixed episodes)	4-week, placebo-controlled trial (5-20 mg/day, starting at 15 mg/day)	Treatment response	Y-MRS	4 weeks	N=115	• **Y-MRS Total Score:** Olanzapine superior to placebo in reduction of Y-MRS total score
Adults with bipolar I disorder (manic or mixed episodes)	Randomized trial following open-label phase (5-20 mg/day)	Time to relapse	Y-MRS, HAM-D 21	Observation period up to 59 days (olanzapine) and 23 days (placebo)	N=361 (olanzapine: 225, placebo: 136)	• **Time to Relapse:** Olanzapine superior to placebo in preventing relapse • **Discontinuation:** 50% of olanzapine group by day 59, 50% of placebo group by day 23

Adjunct to Lithium or Valproate

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with bipolar I disorder (manic or mixed episodes) on lithium or valproate	6-week, placebo-controlled combination trial	Treatment response	Y-MRS	6 weeks	N=175 (Olanzapine: 5-20 mg/day, once daily (starting at 10 mg/day); Lithium: 0.6-1.2 mEq/L; Valproate: 50-125 µg/mL)	• **Y-MRS Total Score:** Olanzapine combined with lithium or valproate superior to lithium or valproate alone in reduction of Y-MRS total score
Adults with bipolar I disorder (manic or mixed episodes) on lithium or valproate	6-week, placebo-controlled combination trial	Treatment response	Y-MRS	6 weeks	N=169	• **Y-MRS Total Score:** Olanzapine combined with lithium or valproate superior to lithium or valproate alone in reduction of Y-MRS total score

Approved Product Analysis: Olanzapine (cont.)

Acute Monotherapy – Adolescents

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Dosage	Magnitude of Improvement
Adolescents (13-17 years) with bipolar I disorder (manic or mixed episodes)	3-week, double-blind, placebo-controlled, randomized trial	Treatment response	Adolescent Structured Y-MRS total score	3 weeks	N=161	Olanzapine: 2.5-20 mg/day (mean modal dose 10.7 mg/day, mean dose 8.9 mg/day)	• **Y-MRS Total Score:** Statistically significantly greater mean reduction for olanzapine compared to placebo

Agitation Associated with Schizophrenia and Bipolar I Mania

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Agitated adult inpatients with schizophrenia	Placebo-controlled trial	Treatment response	PANSS Excited Component	2 hours post-injection	N=270	• **PANSS Excited Component:** All doses (2.5 mg, 5 mg, 7.5 mg, 10 mg) statistically superior to placebo; larger and more consistent effect for 5 mg, 7.5 mg, and 10 mg; no significant pairwise differences for the 7.5 and 10 mg doses over the 5 mg dose
Agitated adult inpatients with schizophrenia	Placebo-controlled trial	Treatment response	PANSS Excited Component	2 hours post-injection	N=311	• **PANSS Excited Component:** 10 mg olanzapine statistically superior to placebo
Agitated adult inpatients with bipolar I disorder (manic or mixed episodes)	Placebo-controlled trial	Treatment response	PANSS Excited Component	2 hours post-injection	N=201	• **PANSS Excited Component:** 10 mg olanzapine statistically superior to placebo

Approved Product Analysis: Quetiapine

Schizophrenia: Short-term Trials –Adults

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with schizophrenia	Study 1: 6-week, fixed-dose, placebo-controlled trial	Treatment response	PANSS total score	6 weeks	N=573	• **SEROQUEL XR 400 mg/day:** Mean change from baseline: -24.8 (2.5), statistically significant vs. placebo (-6.1, CI: -11.5 to -0.6) • **SEROQUEL XR 600 mg/day:** Mean change from baseline: -30.9 (2.5), statistically significant vs. placebo (-12.1, CI: -17.6 to -6.7) • **SEROQUEL XR 800 mg/day:** Mean change from baseline: -31.3 (2.5), statistically significant vs. placebo (-12.5, CI: -17.9 to -7.1) • **SEROQUEL 400 mg/day (twice daily):** Mean change from baseline: -26.6 (2.4), statistically significant vs. placebo (-7.8, CI: -13.1 to -2.4) • **Placebo:** Mean change from baseline: -18.8 (2.5)

Short Term Trials-Adolescents (ages 13-17)

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adolescents (13-17 years) with schizophrenia	Study 2: 6-week, double-blind, placebo-controlled trial	Treatment response	PANSS total score	6 weeks	N=222 (SEROQUEL 400 mg/day: 73, SEROQUEL 800 mg/day: 74, Placebo: 75)	• **SEROQUEL 400 mg/day:** Mean change from baseline: -27.3 (2.6), statistically significant vs. placebo (-8.2, CI: -16.1 to -0.3) • **SEROQUEL 800 mg/day:** Mean change from baseline: -28.4 (1.8), statistically significant vs. placebo (-9.3, CI: -16.2 to -2.4) • **Placebo:** Mean change from baseline: -19.2 (3.0)

Approved Product Analysis: Quetiapine (cont.)

Maintenance Trials

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Clinically stable adult outpatients with schizophrenia	Study 3: Longer-term, double-blind, placebo-controlled trial	Time to relapse	PANSS total score, CGI-S, CGI-I	Up to 7 months	N=171	• **Time to Relapse:** SEROQUEL XR (400-800 mg/day) statistically significant longer time to relapse compared to placebo • **Relapse Criteria:** ≥30% increase in PANSS total score, CGI-I score of ≥6, hospitalization due to worsening of schizophrenia, or need for any other antipsychotic medication

Bipolar I disorder, manic or mixed episodes – Adults

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with bipolar I disorder (manic or mixed episodes)	Study 1: 3-week, placebo-controlled trial	Treatment response	YMRS total score	3 weeks	N=316	• **SEROQUEL XR (400-800 mg/day):** Mean change from baseline: -14.3 (0.9), statistically significant vs. placebo (-3.8, CI: -5.7 to -2.0) • **Placebo:** Mean change from baseline: -10.5 (0.9)

Monotherapy

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with bipolar I disorder (manic episodes)	Study 2: 12-week, placebo-controlled trial	Treatment response	YMRS total score	3 and 12 weeks	N=300	• **SEROQUEL (200-800 mg/day):** Mean change from baseline: -12.3 (1.3), statistically significant vs. placebo (-4.0, CI: -7.0 to -1.0) • **Haloperidol:** Mean change from baseline: -15.7 (1.3), statistically significant vs. placebo (-7.4, CI: -10.4 to -4.4) • **Placebo:** Mean change from baseline: -8.3 (1.3)
Patients with bipolar I disorder (manic episodes)	Study 3: 12-week, placebo-controlled trial	Treatment response	YMRS total score	3 and 12 weeks	N=299	• **SEROQUEL (200-800 mg/day):** Mean change from baseline: -14.6 (1.5), statistically significant vs. placebo (-7.9, CI: -10.9 to -5.0) • **Lithium:** Mean change from baseline: -15.2 (1.6), statistically significant vs. placebo (-8.5, CI: -11.5 to -5.5) • **Placebo + mood stabilizer:** Mean change from baseline: -6.7 (1.6)

Approved Product Analysis: Quetiapine (cont.)

Adjunct Therapy

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with bipolar mania (adjunct to lithium or divalproex)	Study 4: 3-week, placebo-controlled trial	Treatment response	YMRS total score	3 weeks	N=170	• **SEROQUEL (200-800 mg/day) + mood stabilizer:** Mean change from baseline: -13.8 (1.6), statistically significant vs. placebo (-3.8, CI: -7.1 to -0.6) • **Placebo + mood stabilizer:** Mean change from baseline: -10 (1.5)

Children and Adolescents (ages 10-17)

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Children and adolescents (10-17 years) with bipolar I disorder (manic episodes)	3-week, double-blind, placebo-controlled, multicenter trial	Treatment response	YMRS total score	3 weeks	N=284 (SEROQUEL 400 mg/day: 95, SEROQUEL 600 mg/day: 98, Placebo: 91)	• **SEROQUEL 400 mg/day:** Mean change from baseline: -14.3 (0.96), statistically significant vs. placebo (-5.2, CI: -8.1 to -2.3) • **SEROQUEL 600 mg/day:** Mean change from baseline: -15.6 (0.97), statistically significant vs. placebo (-6.6, CI: -9.5 to -3.7) • **Placebo:** Mean change from baseline: -9.0 (1.1)

Approved Product Analysis: Quetiapine (cont.)

Bipolar Disorder, Depressive Episodes – Adults

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with bipolar disorder (depressive episodes)	Study 6: 8-week, randomized, double-blind, placebo-controlled	Treatment response	MADRS total score	8 weeks	N=280	• **SEROQUEL XR 300 mg/day:** Mean change from baseline: -17.4 (1.2), statistically significant vs. placebo (-5.5, CI: -7.9 to -3.2) • **Placebo:** Mean change from baseline: -11.9 (1.2)
Patients with bipolar disorder (depressive episodes)	Study 7: 8-week, randomized, double-blind, placebo-controlled	Treatment response	MADRS total score, Q-LES-Q(SF)	8 weeks	N=522	• **SEROQUEL 300 mg/day:** Mean change from baseline: -16.4 (0.9), statistically significant vs. placebo (-6.1, CI: -8.3 to -3.9) • **SEROQUEL 600 mg/day:** Mean change from baseline: -16.7 (0.9), statistically significant vs. placebo (-6.5, CI: -8.7 to -4.3) • **Placebo:** Mean change from baseline: -10.3 (0.9) • **Quality of Life (Q-LES-Q(SF)):** Statistically significant improvements over placebo for 300 mg dose group
Patients with bipolar disorder (depressive episodes)	Study 8: 8-week, randomized, double-blind, placebo-controlled	Treatment response	MADRS total score, Q-LES-Q(SF)	8 weeks	N=523	• **SEROQUEL 300 mg/day:** Mean change from baseline: -16.9 (1.0), statistically significant vs. placebo (-5.0, CI: -7.3 to -2.7) • **SEROQUEL 600 mg/day:** Mean change from baseline: -16.0 (1.0), statistically significant vs. placebo (-4.1, CI: -6.4 to -1.8) • **Placebo:** Mean change from baseline: -11.9 (1.0) • **Quality of Life (Q-LES-Q(SF)):** Statistically significant improvements over placebo for 300 mg dose group

Approved Product Analysis: Quetiapine (cont.)

Adjunct to Lithium or Valproate

Population	Study	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Patients with bipolar I disorder (maintenance treatment)	Study 9: Placebo-controlled trial	Time to recurrence of a mood event (manic, mixed, or depressed episode)	Kaplan-Meier estimation	280 days (SEROQUEL) and 117 days (placebo)	N=1326	• **Time to Recurrence:** SEROQUEL superior to placebo in increasing time to recurrence of any mood event • **Discontinuation:** 50% of SEROQUEL group discontinued by day 280, 50% of placebo group discontinued by day 117
Patients with bipolar I disorder (maintenance treatment)	Study 10: Placebo-controlled trial	Time to recurrence of a mood event (manic, mixed, or depressed episode)	Kaplan-Meier estimation	280 days (SEROQUEL) and 117 days (placebo)	N=1326	• **Time to Recurrence:** SEROQUEL superior to placebo in increasing time to recurrence of any mood event • **Discontinuation:** 50% of SEROQUEL group discontinued by day 280, 50% of placebo group discontinued by day 117

Summary of Failed Drug Candidates for Bipolar Disorder

Name of Drug	Clinical Trial Identifier	Reason for Termination / Drug Failure
Carbamazepine ER	NCT02623504	No apparent therapeutic effects that was superior to placebo
Sodium Benzoate	GDCT0235621	Although completed, for individuals with early psychosis, there is no evidence that adjunctive use of 500 mg of BZ twice daily is an effective treatment
Allopurinol	NCT00643123	Although completed, findings suggest that allupurinol is not effective than placebo in the reduction of manic symptoms and had no significant benefits when compared to placebo.
Risperidone	NCT00167479	Although completed, findings suggest that risperidone is not effective in subjects with ambulatory bipolar disorder with current at least moderately severe anxiety and lifetime panic disorder or generalized anxiety disorder.
Galantamine Hydrobromide	NCT00741598	Although galantamine is effective for patients with Alzheimers, findings suggest that while galantamine is safe and well tolerated, it is non effective for treatment with cognitive defects in subjects with bipolar disorders.

INGENŪ CRO

Unique Failure Points in Clinical Trials for Bipolar Disorder

1. Heterogeneity of Symptoms:

Bipolar disorder encompasses a broad spectrum of symptoms, including manic, hypomanic, depressive, and mixed episodes. This heterogeneity makes it difficult to standardize diagnostic criteria and select a homogeneous study population.

The variability in symptoms can lead to challenges in patient recruitment and retention, as well as inconsistencies in measuring treatment effects. This heterogeneity complicates the assessment of treatment efficacy and may result in underpowered studies due to the broad range of symptom severity and presentation.

2. High Placebo Response Rates:

Bipolar disorder, like many other psychiatric conditions, is susceptible to high placebo response rates. Patients may show significant improvement due to placebo effects rather than the actual efficacy of the treatment being tested.

High placebo response rates can obscure the true effects of the investigational drug, making it difficult to demonstrate statistically significant differences between the treatment and placebo groups. This can lead to the failure of potentially effective treatments during clinical trials.

3. Long-Term Adherence and Follow-Up:

Bipolar disorder often requires long-term treatment and follow-up to adequately assess the efficacy and safety of interventions. Ensuring patient adherence to treatment protocols and maintaining long-term follow-up are significant challenges.

Non-adherence to treatment protocols can lead to incomplete data and biased outcomes. Patients dropping out of studies or not adhering to medication regimens can result in an inability to accurately assess long-term efficacy and safety, undermining the reliability of the trial results.

4. Comorbid Conditions:

Bipolar disorder frequently co-occurs with other psychiatric and medical conditions, such as anxiety disorders, substance use disorders, and cardiovascular diseases. These comorbidities can complicate the clinical picture and treatment response.

Comorbid conditions can confound the results of clinical trials, making it difficult to isolate the effects of the investigational drug on bipolar disorder alone. They can also affect patient recruitment, as exclusion criteria to control for comorbidities may limit the pool of eligible participants.

Safety Concerns and Standard of Care Treatment Options

Safety Concerns

Medication Side Effects:

- Lithium is effective but has a narrow therapeutic window, and can cause weight gain, tremors, gastrointestinal issues, and increased urine output. Valproate risks include weight gain, liver damage, and teratogenic effects. Atypical antipsychotics can lead to weight gain, metabolic syndrome, diabetes, and dyslipidemia. Lamotrigine can cause a serious skin rash, requiring immediate discontinuation.

Long-Term Treatment Risks:

- Chronic use of mood stabilizers and antipsychotics can lead to metabolic complications, cardiovascular issues, and organ damage. Long-term monitoring and preventive measures are essential to mitigate these risks.

Polypharmacy

- Many patients with bipolar disorder require multiple medications to manage their symptoms effectively. Polypharmacy increases the risk of drug-drug interactions, which can lead to adverse effects and complicate treatment regimens.

Adherence and Compliance

- Non-adherence to medication regimens is a common issue in bipolar disorder, often due to side effects, lack of insight, or complex dosing schedules. Poor adherence can lead to relapse, hospitalization, and increased morbidity.

Standard of Care Treatment Options

Pharmacological Interventions:

- Mood Stabilizers: Lithium and Valproate are the mainstays.
- Antipsychotics: Used to treat acute mania and mixed episodes.
- Antidepressants: Used to treat depressive episodes, and typically combined with a mood stabilizer.
- Anticonvulsants: Lamotrigine is particularly effective in preventing depressive episodes and is often used as maintenance therapy.

Psychotherapy:

- Cognitive Behavioral Therapy (CBT): Helps patients identify and change negative thought patterns and behaviors.
- Psychoeducation: Enhances adherence and empowers patients.
- Interpersonal and Social Rhythm Therapy (IPSRT): Focuses on stabilizing daily routines and improving interpersonal relationships

Lifestyle Modifications

- Regular Sleep Patterns: It is crucial to maintain a consistent sleep schedule is crucial, as disruptions can trigger mood episodes.
- Healthy Diet and Exercise: Reduces the risk of metabolic syndrome.

Regular Monitoring and Follow-Up

- Blood Tests: Necessary to monitor medication levels.
- Mental Health Check-Ins: Essential to monitor symptoms, adjust medications, and provide ongoing support.

INGENŪ CRO

Enhancing Clinical Trial Protocols for Bipolar Disorder

Improving clinical trial protocols is pivotal to advancing our understanding and treatment of Bipolar Disorder. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required for FDA approval.

1. Robust Trial Designs:

- Randomized Controlled Trials (RCTs): Randomization helps eliminate bias, and control groups provide a benchmark for comparing the effects of the investigational treatment.
- Blinding: Double-blind studies, minimize bias and increase the reliability of results. Effective blinding is crucial, especially in psychiatric trials where placebo effects can be substantial.
- Sample Size: Adequate sample size calculations ensure that the study is powered to detect clinically meaningful differences.

2. Patient-Centered Outcomes:

- Incorporating patient-reported outcomes (PROs) into the study design can provide insights into the treatment's impact on patients' quality of life, daily functioning, and overall well-being. PROs are increasingly recognized by regulatory agencies as important measures of treatment benefit.
- Standardized and validated scales, such as the Young Mania Rating Scale (YMRS) for mania and the Hamilton Depression Rating Scale (HDRS) for depression, should be used to assess primary and secondary endpoints consistently.

3. Long-Term Follow-Up:

- Bipolar disorder is a chronic condition with episodic exacerbations. Long-term follow-up is essential to evaluate the sustained efficacy and safety of the treatment. Longitudinal studies can capture data on relapse rates, maintenance of therapeutic effects, and long-term side effects.
- Regular follow-up visits and monitoring ensure comprehensive data collection over extended periods, providing a more complete picture of the treatment's impact.

4. Diverse Population Studies:

- Including diverse demographic groups in clinical trials enhances the generalizability of the results. Trials should aim to recruit participants across different ages, genders, ethnicities, and socioeconomic backgrounds.
- Addressing health disparities by ensuring access to trial participation for underrepresented populations can improve the external validity of the findings and align with FDA recommendations for inclusive research.

Notable Key Opinion Leaders in Bipolar Disorder Research

Name	Specialty	Designation	Location	Brief Bio
Dr. Linda Kader (MBBS, FRANZCP)	Psychiatry	Senior Consultant Psychiatrist, The Royal Melbourne Hospital	Victoria, Australia	Dr. Linda Kader is a Senior Consultant Psychiatrist at the Royal Melbourne Hospital. She holds an honorary fellowship in the Department of Psychiatry at the University of Melbourne. She is certified in Psychodynamic Psychotherapy (Australia), Contemplative Psychotherapy (Nalanda Institute, USA), and Mindfulness Teaching (USA). Additionally, she has studied Global Mental Health and Refugee Trauma at Harvard University, where she also served as a visiting faculty member.
Dr. Astrid Waterdrinker (MBBS, Mmed, MRCPsych)	Psychology	Consultant Psychiatrist, The Royal Melbourne Hospital	Victoria, Australia	Dr. Astrid Waterdrinker is a Consultant Psychiatrist at the Royal Melbourne Hospital. She is also associated with the North West Area Mental Health Service, which is part of Melbourne Health. Dr. Waterdrinkers contributions to society include her involvement in clinical trials and research studies aimed at improving mental health treatment strategies, particularly for bipolar disorder and other mood disorders. She works collaboratively with multidisciplinary teams to provide comprehensive mental health care.
Dr. Remy McCubbin (BSc (Biology), MA (Psych), PhD (Clin Psych))	Psychiatry	Clinical Psychologist, Kensington Psychology and Well-Being	South Australia	Dr. Remy McCubbin is a highly experienced clinical psychologist based in Kensington Park, South Australia. He specializes in treating a variety of mental health issues, including bipolar disorder, depression, anxiety, trauma, and personality disorders. He is a registered psychologist with the Australian Health Practitioner Regulation Agency (AHPRA) and is a member of the Australian Association for Cognitive and Behaviour Therapy.
Dr. Steven Chau (MBBS, BA (Psychology), MPSYCH, FRANZCP)	Psychiatry	Director, Melbourne Mental Health	Victoria, Australia	Dr. Steven Chau is a senior consultant psychiatrist and the Director of Melbourne Mental Health. He has over a decade of experience in psychiatry, specializing in sports psychiatry, ADHD, mood and anxiety disorders, and obsessive-compulsive disorder. Dr. Chau is particularly known for his work with elite athletes and high-performing professionals, managing their mental health to enhance both personal well-being and professional performance.
Dr. Julanne Frater (MBBS, RANZCP, FRANZCP)	Psychiatry	Consultant Psychiatrist, The Alfred Hospital	Victoria, Australia	Dr. Julanne Frater is a highly accomplished Consultant Psychiatrist at Melbourne Mental Health. She has extensive experience in multiple areas of psychiatry, having worked in both public and private hospital settings. Her special interests include neuropsychiatry, perinatal mental health, ADHD, autism, and general adult psychiatry. Dr. Frater has worked in various prestigious institutions, including the Mater Advanced Epilepsy Unit and the Alfred Hospital in Melbourne, where she focused on epilepsy and functional neurological disorders.

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com